Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Passage Bio Inc PASG

Healthcare Biotechnology
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional... see more

Recent & Breaking News (NDAQ:PASG)

Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis

GlobeNewswire May 21, 2020

Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting

GlobeNewswire May 12, 2020

Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights

GlobeNewswire May 11, 2020

Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania

GlobeNewswire May 7, 2020

Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020

GlobeNewswire May 4, 2020

FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis

GlobeNewswire April 21, 2020

Passage Bio to Present at 19th Annual Needham Healthcare Conference

GlobeNewswire April 8, 2020

Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

GlobeNewswire March 27, 2020

Passage Bio Announces Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire March 9, 2020

Passage Bio Appoints Athena Countouriotis to Board of Directors

GlobeNewswire March 5, 2020

Passage Bio Announces Pricing of Initial Public Offering

GlobeNewswire February 27, 2020